Fondaparinux Anti-Xa
Also known as: Arixtra®
Use
Monitor prophylactic fondaparinux levels in patient plasma6
Special Instructions
Citrated plasma samples should be collected by double centrifugation. It's crucial to ensure a proper blood to anticoagulant ratio by filling evacuated collection tubes to completion. Immediate mixing by gentle inversion is recommended at least six times. Adequate sample stability is necessary by avoiding platelet activation and sample contamination with heparin.
Limitations
Severe hemolysis, bilirubinemia, and lipemia may interfere with this assay. Improper sample preparation or handling, especially post-freezing, may also alter results. Platelet factor 4 release due to inadequate platelet removal can falsely lower fondaparinux concentrations. The assay lacks a manufacturer-established therapeutic range and its performance characteristics should not be used solely for treatment or diagnostic purposes without corroboration from other medically established diagnostic procedures.
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 74217-1
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
1 mL
Minimum Volume
Not provided
Container
Blue-top (sodium citrate) tubes
Collection Instructions
Citrate plasma collected by double centrifugation in a blue-top tube containing 3.2% sodium citrate. Tubes must be filled completely. Mix immediately six times for adequate anticoagulant mixing. After centrifugation, transfer plasma to Labcorp PP transpak frozen purple tube with screw cap and freeze immediately.
Storage Instructions
Freeze. Stable refrigerated for four hours.
Causes for Rejection
Hemolysis; clotted specimen; specimen contaminated with heparin
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 4 hours |